Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Klümpen HJ, Chan SL, Ozaka M, Verslype C, Bouattour M, Park JO, Barajas O, Pelzer U, Valle JW, Yu L, Malhotra U, Siegel AB, Edeline J, Vogel A; KEYNOTE-966 Investigators. Kelley RK, et al. Among authors: ozaka m. Lancet. 2023 Jun 3;401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4. Epub 2023 Apr 16. Lancet. 2023. PMID: 37075781 Clinical Trial.
Adherence to the guidelines and the pathological diagnosis of high-risk gastrointestinal stromal tumors in the real world.
Nishida T, Sakai Y, Takagi M, Ozaka M, Kitagawa Y, Kurokawa Y, Masuzawa T, Naito Y, Kagimura T, Hirota S; members of the STAR ReGISTry Study Group. Nishida T, et al. Among authors: ozaka m. Gastric Cancer. 2020 Jan;23(1):118-125. doi: 10.1007/s10120-019-00966-4. Epub 2019 Apr 30. Gastric Cancer. 2020. PMID: 31041650 Free PMC article.
[A case of small pancreatic cancer with intraductal progress].
Fukuba N, Fujita K, Nakayama S, Takenaka M, Matsui S, Ozaka M, Shibagaki K, Yoshinaga H, Masuzawa A, Watanabe A, Fujiwara H, Sugahara A, Fujita T, Mukai H, Tsukamoto T, Teramura K. Fukuba N, et al. Among authors: ozaka m. Nihon Shokakibyo Gakkai Zasshi. 2010 May;107(5):792-7. Nihon Shokakibyo Gakkai Zasshi. 2010. PMID: 20460854 Japanese.
Complete response of a pancreatic adenosquamous carcinoma to chemoradiotherapy.
Shibagaki K, Fujita K, Nakayama S, Takenaka M, Fukuba N, Matsui S, Ozaka M, Yoshinaga H, Masuzawa A, Watanabe A, Fujiwara H, Sugawara A, Fujita T, Mukai H, Kinoshita Y. Shibagaki K, et al. Among authors: ozaka m. Int J Clin Oncol. 2008 Feb;13(1):74-7. doi: 10.1007/s10147-007-0690-x. Epub 2008 Feb 29. Int J Clin Oncol. 2008. PMID: 18307024
Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan.
Todaka A, Mizuno N, Ozaka M, Ueno H, Kobayashi S, Uesugi K, Kobayashi N, Hayashi H, Sudo K, Okano N, Horita Y, Kamei K, Yukisawa S, Nakamori S, Yachi Y, Henmi T, Kobayashi M, Boku N, Mori K, Fukutomi A. Todaka A, et al. Among authors: ozaka m. Pancreas. 2018 May/Jun;47(5):631-636. doi: 10.1097/MPA.0000000000001049. Pancreas. 2018. PMID: 29683973
Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407).
Mizusawa J, Fukutomi A, Katayama H, Ishii H, Ioka T, Okusaka T, Ueno H, Ueno M, Ikeda M, Mizuno N, Ozaka M, Fukuda H, Furuse J; Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group. Mizusawa J, et al. Among authors: ozaka m. Pancreatology. 2018 Oct;18(7):841-845. doi: 10.1016/j.pan.2018.07.007. Epub 2018 Jul 27. Pancreatology. 2018. PMID: 30075908 Clinical Trial.
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.
Morizane C, Okusaka T, Mizusawa J, Katayama H, Ueno M, Ikeda M, Ozaka M, Okano N, Sugimori K, Fukutomi A, Hara H, Mizuno N, Yanagimoto H, Wada K, Tobimatsu K, Yane K, Nakamori S, Yamaguchi H, Asagi A, Yukisawa S, Kojima Y, Kawabe K, Kawamoto Y, Sugimoto R, Iwai T, Nakamura K, Miyakawa H, Yamashita T, Hosokawa A, Ioka T, Kato N, Shioji K, Shimizu K, Nakagohri T, Kamata K, Ishii H, Furuse J; members of the Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG). Morizane C, et al. Among authors: ozaka m. Ann Oncol. 2019 Dec 1;30(12):1950-1958. doi: 10.1093/annonc/mdz402. Ann Oncol. 2019. PMID: 31566666 Free article. Clinical Trial.
139 results